General Comments / Chat, page-6538

Reminder of the news expected (plus a couple bonus ones perhaps as a part of the Iceberg?)

In H1 CY 2023, shareholders can expect:
Clinical
o Updates on the Phase 2 relapsed/refractory (R/R) AML combination trial in Israel
o Updates on the Phase 1/2 EMD AML trial with first patient recruitment expected
o Updates on new Zantrene formulation manufacturing progress.
Preclinical
o Updates on both cell and animal studies supporting the cardioprotection program
o Updates on cell and animal studies exploring the optimal combination of Zantrene with the standard of care drugs doxorubicin and cyclophosphamide
o Updates on dose ranging studies of Zantrene and a kinase inhibitor in a rat model of clear cell renal cell carcinoma (kidney cancer)
o Updates on dose ranging and cardioprotection studies in mouse models of multiple myeloma and cardioprotection
o An update on a human derived mouse model of AML study, exploring the optimal combination of decitabine and Zantrene as a low toxicity treatment for AML
o Updates on studies exploring the potential utility of Zantrene as an anti-cancer agent across more than 100 cancer types.